ライフサイエンスコーパス: axillary

1 -80 years) underwent high-spatial-resolution axillary 3.0-T T2-weighted imaging without fat suppressi

2 ercentile of the distribution) after 3-level axillary, 3-level or less neck, 4-level or more neck, in

3 tive LR, 3.1 [95% CI, 1.6-5.9]), inguinal or axillary adenopathy (specificity range, 0.82-0.91; posit

4 T1 or T2 invasive breast cancer, no palpable axillary adenopathy, and 1 or 2 sentinel lymph nodes con

5 invasive primary breast cancer, no palpable axillary adenopathy, and 1 or 2 sentinel lymph nodes con

6 presence of posterior cervical, inguinal or axillary adenopathy, palatine petechiae, splenomegaly, o

7 There was no palpable axillary adenopathy.

8 severe truncal hirsutism and higher rates of axillary AN.

9 Patients with axillary and breast pCR after PST had superior long-term

10 ferating cells were detected in lymph nodes (axillary and mesenteric).

11 examination, she had adenopathy in the left axillary and supraclavicular regions, fullness in the le

12 ternal mammary nodes and the supraclavicular-axillary apical nodes in addition to the chest wall or r

13 We collected and tested axillary, blood, conjunctival, forehead, mouth, rectal,

14 ngth distribution and consensus sequences in axillary, brachial, inguinal, and mesenteric LNs were vi

15 Axillary branch suppression is a favorable trait bred in

16 Here, we show that tb1 mediates axillary branch suppression through direct activation of

17 nated from ectopic overexpression of tru1 in axillary branches, a critical step in mediating the effe

18 in auxin signaling (AUXIN RESISTANT1), MORE AXILLARY BRANCHING (MAX) signaling (MAX2), and BRANCHED1

19 psis (Arabidopsis thaliana) both by delaying axillary bud activation and by attenuating the basipetal

20 o) and phosphate availability, such that the axillary bud at node 7 varied from deeply dormant to rap

21 gene to characterize D14 function from early axillary bud development through to lateral shoot outgro

22 at axil and leaf boundary regions to control axillary bud differentiation as well as the development

23 EBE overexpression also stimulates axillary bud formation and outgrowth, while repressing i

24 scription factor that acts as a repressor of axillary bud growth.

25 he miR156 targets, directly regulated aerial axillary bud initiation.

26 reby the impact of any SL signal reaching an axillary bud is modulated by the responsiveness of these

27 hoot tip's strong demand for sugars inhibits axillary bud outgrowth by limiting the amount of sugar t

28 polar auxin transport stream (PATS) inhibits axillary bud outgrowth, its role in regulating the phyB

29 ght and nutrition, are integrated within the axillary bud to promote or suppress the growth of the bu

30 ision during branch development: whether the axillary bud, or branch primordium, grows out to give a

31 otein (RanBP) in Arabidopsis results in more axillary buds and reduced apical dominance compared to W

32 the main stem and inhibits the growth of the axillary buds below it, contributing to apical dominance

33 owing shoot tip suppresses the growth of the axillary buds below.

34 fruit removal resembled changes observed in axillary buds following release from apical dominance.

35 ipt is regulated by light quality, such that axillary buds growing in added far-red light have greatl

36 ced tillering, deregulation of the number of axillary buds in an axil, and alterations in leaf proxim

37 The outgrowth of axillary buds into branches is regulated systemically vi

38 ression of auxin transport/canalization from axillary buds into the main stem and is enhanced by a lo

39 rs are vegetative branches that develop from axillary buds located in the leaf axils at the base of m

40 Colchicine treatment of axillary buds resulted in a set of autotetraploid S. vim

41 buted over large distances and accumulate in axillary buds within a timeframe that correlates with bu

42 mportant role in inhibiting the outgrowth of axillary buds, a phenomenon known as apical dominance.

43 The expression of TRU1 and TB1 overlap in axillary buds, and TB1 binds to two locations in the tru

44 Grasses possess basal and aerial axillary buds.

45 nins and strigolactones, which can move into axillary buds.

46 abidopsis is determined by the activation of axillary buds.

47 ntinel node provide excellent and comparable axillary control for patients with T1-2 primary breast c

48 Despite the potential for residual axillary disease after SLND, SLND without ALND offers ex

49 imal RT approach in patients with low-volume axillary disease treated with SLND alone.

50 For patients with residual axillary disease, 10-year OS rates were 66% (95% CI, 56%

51 demonstrated reduced size of the breast and axillary disease, and no significant residual PET avidit

52 01) for those with axillary pCR and residual axillary disease, respectively.

53 for patients with axillary pCR and residual axillary disease, respectively.

54 2,M0 breast cancer underwent SLN surgery and axillary dissection (ALND) after neoadjuvant chemotherap

55 To determine rates of axillary dissection (ALND) and nodal recurrence in patie

56 he status of the nodal basin and if targeted axillary dissection (TAD), which includes sentinel lymph

57 When clinicians and patients elect to omit axillary dissection after a positive sentinel node biops

58 Targeted axillary dissection or selective removal of lymph nodes

59 Avoidance of axillary dissection significantly reduces the morbidity

60 modality breast cancer treatment can replace axillary dissection when breast-conserving therapy is un

61 mber of excised LNs were as follows: 3-level axillary dissection, 20 (15-27) and 22 (8); 3-level or l

62 d selectively removed to accomplish targeted axillary dissection, which is technically possible after

63 is noninferior to that of women treated with axillary dissection.

64 Axillary drainage in naive mice and from healthy and tum

65 nt (30 of 30 [100%] for readers 1 and 2) and axillary (eight of eight [100%] for reader 1, seven of e

66 volume was the most significant predictor of axillary evaluation among women undergoing BCS (mid vs l

67 ective evaluation of the clinical benefit of axillary evaluation in women with DCIS is needed.

68 Rates of axillary evaluation increased over time with mastectomy

69 Despite uncertainty regarding the efficacy, axillary evaluation is often performed in women with DCI

70 ion (RR, 1.15; 95% CI, 1.03-1.29) influenced axillary evaluation with mastectomy.

71 Receipt or nonreceipt of surgical axillary evaluation, categorized as sentinel lymph node

72 g BCS and 63.0% undergoing mastectomy had an axillary evaluation.

73 was used to identify factors associated with axillary evaluation.

74 d the strigolactone biosynthesis mutant more axillary growth1, increased retention of basal branches

75 (Skp, Cullin, F-box) complex component MORE AXILLARY GROWTH2 (MAX2) [3-5].

76 sis thaliana requires the F-box protein MORE AXILLARY GROWTH2 (MAX2).

77 equired for the development of multicellular axillary hairs on the gametophyte of the moss Physcomitr

78 We confirm that even without preoperative axillary imaging or routine use of nodal RT, ALND can be

79 Axillary imaging was not routine.

80 y expressed in the leaf trace vasculature of axillary internodes, while in teosinte, this expression

81 able beyond 10 years, even for those with no axillary involvement (2.0%, 2.1%, and 1.1% for years 10

82 lvement, or an externally located tumor with axillary involvement to undergo either whole-breast or t

83 ological tumour size >20 mm, with or without axillary involvement), at 66 centres in the UK.

84 ially located primary tumor, irrespective of axillary involvement, or an externally located tumor wit

85 size, between SUVmax-T values and metastatic axillary LN size, between SUVmax-T and SUVmax-LN values,

86 lary LNs, between tumour size and metastatic axillary LN size, between SUVmax-T values and metastatic

87 PET/CT parameters including tumour size, axillary LN size, SUVmax of ipsilateral axillary LNs (SU

88 ad the lowest LN activity (mean [SD] maximum axillary LN standardized uptake value, 1.53 [0.56]), the

89 intermediate levels of LN (mean [SD] maximum axillary LN standardized uptake value, 2.12 [0.87] and 2

90 had the highest activity (mean [SD] maximum axillary LN standardized uptake value, 8.82 [3.08]).

91 ondary lymphoid tissues (spleen, ipsilateral axillary LN, and contralateral inguinal LN) were removed

92 ize, axillary LN size, SUVmax of ipsilateral axillary LNs (SUVmax-LN), SUVmax of primary tumour (SUVm

93 the size and SUVmax-LN values of metastatic axillary LNs, between tumour size and metastatic axillar

94 f the primary tumour and those of metastatic axillary LNs.

95 accurate exclusion of clinically significant axillary lymph node (ALN) disease.

96 peripheral blood (PB), bone marrow (BM), and axillary lymph node (ALN) tissue of rhesus macaques infe

97 peripheral blood (PB), bone marrow (BM), and axillary lymph node (ALN) tissue of rhesus macaques infe

98 group included 17 patients with ipsilateral axillary lymph node (LN) metastases.

99 P < .001), high body mass index ( P = .039), axillary lymph node dissection ( P = .008), and more sev

100 cer diagnosis ( P = .0404), having undergone axillary lymph node dissection ( P = .0464), and receipt

101 SLNB has replaced axillary lymph node dissection (ALND) as the staging mod

102 staging information with less morbidity than axillary lymph node dissection (ALND) for patients with

103 node biopsy (SLNB) was developed to replace axillary lymph node dissection (ALND) for staging early

104 l lymph node dissection (SLND) alone without axillary lymph node dissection (ALND) is noninferior to

105 ACOSOG Z0011 established that axillary lymph node dissection (ALND) is unnecessary in

106 n both sentinel lymph node biopsy (SLNB) and axillary lymph node dissection (ALND) may be because of

107 inel lymph nodes (SLNs) randomized either to axillary lymph node dissection (ALND) or sentinel lymph

108 After NAC, SLN surgery and axillary lymph node dissection (ALND) were planned.

109 orized as sentinel lymph node biopsy (SLNB), axillary lymph node dissection (ALND), or none.

110 mph node (SLN) metastases should not receive axillary lymph node dissection (ALND).

111 mph node (SLN) metastases should not receive axillary lymph node dissection (ALND).

112 included body mass index >/= 25 (P = .0236), axillary lymph node dissection (P < .001), regional lymp

113 Axillary lymph node dissection (P < 0.0001), higher body

114 2 patients were randomly assigned to receive axillary lymph node dissection and 2404 to receive axill

115 inel node, 744 had been randomly assigned to axillary lymph node dissection and 681 to axillary radio

116 Axillary lymph node dissection and axillary radiotherapy

117 d the localized lymph node before completion axillary lymph node dissection and used radiography of t

118 lar to upfront SLNB and reduces the need for axillary lymph node dissection compared with SLNB prior

119 me progressively less extensive, with formal axillary lymph node dissection confined to a dwindling g

120 ence occurred in four of 744 patients in the axillary lymph node dissection group and seven of 681 in

121 In the axillary lymph node dissection group, 220 (33%) of 672 p

122 py group compared with an expected 2% in the axillary lymph node dissection group.

123 oup, 220 (33%) of 672 patients who underwent axillary lymph node dissection had additional positive n

124 ymph nodes (SLNs) are recommended to undergo axillary lymph node dissection if extranodal extension (

125 east cancers while avoiding the morbidity of axillary lymph node dissection if the nodes do not conta

126 Indications for omission of completion axillary lymph node dissection in patients with two or f

127 These findings do not support routine use of axillary lymph node dissection in this patient populatio

128 st cancer who have a positive sentinel node, axillary lymph node dissection is the present standard.

129 erated allocation schedule to receive either axillary lymph node dissection or axillary radiotherapy

130 Although axillary lymph node dissection provides excellent region

131 arm was noted significantly more often after axillary lymph node dissection than after axillary radio

132 ecurrence was 0.43% (95% CI 0.00-0.92) after axillary lymph node dissection versus 1.19% (0.31-2.08)

133 A complementary axillary lymph node dissection was performed in all pati

134 patients undergoing total mastectomy and/or axillary lymph node dissection were randomized to standa

135 the ability to achieve the results of total axillary lymph node dissection without the risks of surg

136 .4% underwent an initial SLNB, 37.2% initial axillary lymph node dissection, and 6.3% no axillary sur

137 eoadjuvant chemotherapy reduces the need for axillary lymph node dissection, and SLNB is an accurate

138 We have previously found that axillary lymph node dissection, both clinically and in a

139 Two patients did not undergo subsequent axillary lymph node dissection, leaving 95 patients for

140 y, followed by breast-conserving surgery and axillary lymph node dissection, which revealed residual

141 s of any size continue to mandate completion axillary lymph node dissection.

142 is an accurate, less invasive alternative to axillary lymph node dissection.

143 of NAC, all patients had breast surgery with axillary lymph node dissection.

144 either sentinel lymph node biopsy (SLNB) or axillary lymph node dissection.

145 r to overall survival for those treated with axillary lymph node dissection.

146 s practice pattern could lead to unnecessary axillary lymph node dissections and lymphedema.

147 Despite guidelines recommending against axillary lymph node evaluation in women with DCIS underg

148 Although axillary lymph node evaluation is standard of care in th

149 years or older without prior chemotherapy or axillary lymph node involvement and (2) the hypofraction

150 , age, comorbid disease, prior chemotherapy, axillary lymph node involvement, intensity-modulated rad

151 50 years or those with prior chemotherapy or axillary lymph node involvement.

152 had a breast pCR and 100% had no evidence of axillary lymph node metastases after NCT.

153 d with a 1% to 3% reduction in recurrence of axillary lymph node metastases, but is associated with a

154 primary tumor subclones, or subclones in an axillary lymph node metastasis.

155 t to substitute it for SLNB for exclusion of axillary lymph node metastasis.

156 IA) during transport from the forepaw to the axillary lymph node region of a rat.

157 The existing standard for axillary lymph node staging in breast cancer patients wi

158 A tumor-positive axillary lymph node was marked with a I seed in 100 pati

159 The MARI procedure [marking the axillary lymph node with radioactive iodine (I) seeds] i

160 needle aspiration of a palpable, ipsilateral axillary lymph node.

161 Two of the 11 axillary lymph nodes contained metastatic carcinoma.

162 Axillary lymph nodes marked with a clip can be localized

163 Prior to NST, proven tumor-positive axillary lymph nodes were marked with a I seed.

164 uding internal mammary, supraclavicular, and axillary lymph nodes) (nodal-irradiation group) or whole

165 bsence of invasive disease in the breast and axillary lymph nodes, analysed by intention to treat.

166 were obtained for the primary breast tumor, axillary lymph nodes, and extraaxillary lymph nodes on e

167 were obtained for the primary breast tumor, axillary lymph nodes, and extraaxillary lymph nodes.

168 ith combined ART, uptake of [18F]-FDG in the axillary lymph nodes, as measured by TBR, decreased from

169 ion took into account the number of involved axillary lymph nodes, clinical tumour stage, oestrogen-r

170 ns of macrophages isolated from the spleens, axillary lymph nodes, colons, jejuna, and livers of heal

171 d cervical lymph nodes but fewer than 20% of axillary lymph nodes, livers, brown fat samples, kidneys

172 for drainage into the cervical, inguinal, or axillary lymph nodes, respectively.

173 tion system (balanced for number of involved axillary lymph nodes, tumour stage, oestrogen receptor s

174 ologic complete response (pCR) in breast and axillary lymph nodes.

175 absence of invasive cancer in the breast and axillary lymph nodes.

176 ly 3 cm on exam, and multiple palpable right axillary lymph nodes.

177 multiple conglomerated 1-2 cm level I and II axillary lymph nodes.

178 sentinel-lymph-node involvement, completion axillary-lymph-node dissection can be omitted or replace

179 The previously undisputed gold standard of axillary-lymph-node dissection for staging has now been

180 s determined in patients undergoing complete axillary lymphadenectomy (ALND).

181 cal examination revealed no palpable mass or axillary lymphadenopathy.

182 quadrant of the left breast with no palpable axillary lymphadenopathy.

183 ode biopsies has increased the complexity of axillary management, and any policy of de-escalation and

184 l response with resolution of the breast and axillary masses on exam.

185 hich differentiate in the final iteration of axillary meristem branching.

186 x) gene, which is expressed primarily in the axillary meristem dome and primordia and in developing s

187 ng directly controls boundary domains during axillary meristem formation and define a fundamental mec

188 ow that STM mobility is required to suppress axillary meristem formation during embryogenesis, to mai

189 auxin from leaf axils is a prerequisite for axillary meristem formation during vegetative developmen

190 However, the role of auxin in the process of axillary meristem formation is largely unknown.

191 HLH) transcriptional regulator necessary for axillary meristem formation that shows a striking bounda

192 n biosynthesis in leaf axils interferes with axillary meristem formation, whereas repression of auxin

193 mises auxin depletion from the leaf axil and axillary meristem initiation.

194 tant, indicating that GA biosynthesis in the axillary meristem is essential for inducing stolon diffe

195 the number, the position and the fate of the Axillary Meristems (AMs).

196 mall groups of pluripotent stem cells called axillary meristems are required for the formation of the

197 flower1, GA2oxidase, and TPPI could protect axillary meristems in phyB-1 from precocious floral indu

198 ts1 (mos1) mutant had an increased number of axillary meristems produced from inflorescence meristem

199 When FveGA20ox4 is mutated, axillary meristems remain dormant or produce secondary s

200 d is rapidly and transiently up-regulated in axillary meristems upon main stem decapitation.

201 To ensure the proper formation of new axillary meristems, the specification of boundary region

202 a plants display a squa phenotype developing axillary meristems, which can eventually turn into inflo

203 y the organization and developmental fate of axillary meristems.

204 tages II to III with cytologically confirmed axillary metastases between 1989 and 2007 who received P

205 tional responders to NCT with a low risk for axillary metastases when breast pCR is documented who ma

206 28 of 29 [96%] for readers 3 and 4, P = .50; axillary metastatic disease: seven of eight [88%] for re

207 After 3-level axillary (n = 1150), 3-level or less neck (n = 77), 4-le

208 he roles of preoperative imaging in defining axillary nodal burden, deselection of patients for senti

209 Patients with axillary nodal involvement after neoadjuvant systemic th

210 r, Houston, Texas, included 12 patients with axillary nodal metastases confirmed by results of fine-n

211 Of 21 patients with pathologically proven axillary nodal metastases, (18)F-fluciclovine-avid axill

212 In view of the declining influence of axillary nodal status on adjuvant therapy decision-makin

213 Fine needle aspiration of a right axillary node confirmed metastatic carcinoma.

214 e underwent partial mastectomy, with partial axillary node dissection and sentinel node mapping.

215 e evidence of benefit from surgical complete axillary node dissection compared with sentinel node bio

216 breast cancer, she underwent mastectomy and axillary node dissection for a left-sided breast cancer

217 breast cancer, she underwent mastectomy and axillary node dissection for a left-sided breast cancer,

218 Complete axillary node dissection in patients with no palpable ly

219 and in the presence of a technical failure, axillary node dissection should be performed.

220 She underwent quadrantectomy and axillary node dissection.

221 ad more than 4 positive nodes at the time of axillary node dissection.

222 surgeon recommended a right mastectomy with axillary node dissection.

223 udy, including 6 who underwent mastectomy or axillary node dissection.

224 rs at the time of study entry; 157 (11%) had axillary node-negative disease; 1142 (76%) had ER-positi

225 Patients with axillary node-negative or nodal micrometastases, estroge

226 Premenopausal women with axillary node-negative, hormone receptor-positive breast

227 ged low-risk (ie, hormone receptor-positive, axillary node-negative, T1-T2 up to 3 cm at the longest

228 3 cm or less (pT1-2), none to three positive axillary nodes (pN0-1), and minimum microscopic margins

229 y its use without needing to know additional axillary nodes are involved.

230 east cancers in 17 patients, and 19 positive axillary nodes in eight patients.

231 tients randomized to ALND had a median of 17 axillary nodes removed compared with a median of only 2

232 ry nodal metastases, (18)F-fluciclovine-avid axillary nodes were seen in 20.

233 For women with no suspicious, palpable axillary nodes who undergo breast-conserving therapy, th

234 3 (50%) patients had clinical involvement of axillary nodes, 276 (33%) patients had oestrogen recepto

235 1-2 breast cancer with one to three positive axillary nodes.

236 astatic carcinoma was identified in 10 of 13 axillary nodes.

237 with the Mendelian trait of earwax, although axillary odor is also Mendelian.

238 The long-term effect of axillary pathologic complete response (pCR) on survival

239 h node-positive breast cancer will obtain an axillary pathologic complete response after neoadjuvant

240 (95% CI, 18%-68%) (P < .001) for those with axillary pCR and residual axillary disease, respectively

241 5% CI, 46%-53%) (P < .001) for patients with axillary pCR and residual axillary disease, respectively

242 d high rates of axillary pCR, and those with axillary pCR had excellent 10-year OS.

243 We retrospectively analyzed the effect of axillary pCR on 10-year OS and RFS among all women who r

244 Axillary pCR was associated with improved 10-year OS and

245 For patients with axillary pCR, 10-year OS rates were 90% (95% CI, 84%-94%

246 for HER2-positive disease had high rates of axillary pCR, and those with axillary pCR had excellent

247 A total of 454 (28.4%) achieved axillary pCR.

248 ositive disease, 67.1% (100 of 149) achieved axillary pCR; 10-year OS rates were 92% (95% CI, 84%-96%

249 Axillary lymph node dissection and axillary radiotherapy after a positive sentinel node pro

250 er axillary lymph node dissection than after axillary radiotherapy at 1 year, 3 years, and 5 years.

251 e, considered to be not more than 4% for the axillary radiotherapy group compared with an expected 2%

252 ode dissection group and seven of 681 in the axillary radiotherapy group.

253 ive either axillary lymph node dissection or axillary radiotherapy in case of a positive sentinel nod

254 We aimed to assess whether axillary radiotherapy provides comparable regional contr

255 Axillary radiotherapy results in significantly less morb

256 ode dissection can be omitted or replaced by axillary radiotherapy, reducing morbidity.

257 ry lymph node dissection and 2404 to receive axillary radiotherapy.

258 de dissection versus 1.19% (0.31-2.08) after axillary radiotherapy.

259 to axillary lymph node dissection and 681 to axillary radiotherapy; these patients constituted the in

260 Axillary recurrence occurred in four of 744 patients in

261 Axillary recurrence rate was 0.2% and 1.4% for SLNB and

262 5-year axillary recurrence was 0.43% (95% CI 0.00-0.92) after a

263 tics, crossover rates, blue node metastases, axillary recurrence, and lymphedema as measured by volum

264 imary endpoint was non-inferiority of 5-year axillary recurrence, considered to be not more than 4% f

265 ates of metastases in noncrossover nodes and axillary recurrences are low.

266 val after SLN alone was 93% with no isolated axillary recurrences.

267 Axillary reverse mapping (ARM) facilitates identificatio

268 ll as the expected medial, pleural series of axillary sclerites.

269 nts grown in vitro were dwarf, with abundant axillary shoot growth, greater tuber yield, altered tube

270 does not affect the lateral root formation, axillary shoot growth, or senescence phenotypes of max2.

271 ants exhibited a lower tuber yield and fewer axillary shoots compared to wild type.

272 zed to undergo ALND after SLND or no further axillary specific treatment.

273 ailable from pathologic review of breast and axillary specimens from surgery after chemotherapy.

274 The clinical interest of axillary staging after neoadjuvant chemotherapy is incre

275 de biopsy (SLNB) is the standard of care for axillary staging in patients with clinically node-negati

276 and provide a minimally invasive method for axillary staging of breast cancer.

277 opsy (SLNB) has become the gold standard for axillary staging.

278 Women were stratified by post-PST axillary status, and survival outcomes were estimated an

279 Both A (radial/brachial) and B (axillary/subclavian/innominate) variants exhibited conco

280 fter neoadjuvant therapy, patients underwent axillary surgery and the pathology of the clipped node w

281 he risk for missing nodal metastases without axillary surgery in this cohort is extremely low.

282 alternative to SLNB in these patients, where axillary surgery is no longer considered therapeutic, an

283 of surgical morbidity by restricting further axillary surgery or considering radiotherapy in patients

284 When stratified by type of axillary surgery, 5-year lymphedema risk was 6.8% in whi

285 tomy, who previously underwent breast and/or axillary surgery, or who received preoperative/neoadjuva

286 tomy, who previously underwent breast and/or axillary surgery, or who received preoperative/neoadjuva

287 motherapy and is easily performed with other axillary surgery, such as SLN dissection.

288 S is recommended after chemotherapy to guide axillary surgery.

289 axillary lymph node dissection, and 6.3% no axillary surgery.

290 Dedicated high-spatial-resolution axillary T2-weighted MR imaging showed good specificity

291 esented with tympanic (>/=38.0 degrees C) or axillary temperature (>/=37.5 degrees C).

292 m participants >/=2 years of age with fever (axillary temperature of >/=37.5 degrees C) or with a his

293 ae and sheaths, and between the mainstem and axillary tillers) to model the dynamics of canopy develo

294 ked lymph node may be used to tailor further axillary treatment after NST.

295 y identified 65 of 70 patients with residual axillary tumor activity (false negative rate 5/70 = 7%).

296 secondary end point was to determine whether axillary ultrasound (AUS) after NAC after fine-needle as

297 Assess the performance characteristics of axillary ultrasound (AUS) for accurate exclusion of clin

298 tion of endotracheal tube.Recent interest in axillary vein cannulation with ultrasound guidance has g

299 Contralateral infraclavicular axillary vein sizes within the same patient are signific

300 Vascular access was via the left axillary vein.